TP53 and breast cancer: Mutant TP53 promotes the development and progression of BC through inhibition of apoptosis, alteration of DNA methylation patterns, activation of oncogenic pathways (e.g., PI3K/AKT/mTOR pathway), induction of multiple metabolic changes, modulation of TME with immunosuppressive changes and enhancement of metastatic potential (26, 34–37).